Építés alatt – nem éles oldal
Belépés
LeállítvaFázis nélkül

ScentAware and OCT in MCI vs HC

A legfontosabb adatok

Ki végzi
University of Wisconsin, Madison
Hol
Madison (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Leállítva
Résztvevők
20 fő vett részt
Kezdés
2024. ápr. 15.
Befejezés
2024. jún. 5.
A vizsgálat típusa
Megfigyeléses, 3 csoport
A vizsgált kezelések
  • ScentAware
  • UPSIT
A regiszteradat frissítve
2025. április 23.
Miért állt le
slow enrollment

Ki vehet részt

Életkor
50 év – 80 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 16 feltétel megnézéseKevesebb

Ki vehet részt

  • Adults who are ≥ 50 and ≤ 80 years of age
  • Fluent in English
  • Able to provide written consent
  • Able to complete a 2.5-3-hour clinical visit, including sitting for spectral domain optical coherence tomography (SD-OCT) imaging for 30 minutes and taking cognitive and olfactory tests for 90-120 minutes
  • Cognitive Ability and Family History of Alzheimer's Disease/Mild Cognitive Impairment (AD/MCI):; Cohort 1: Cognitively unimpaired, no family history of MCI or AD, and MMSE ≥ 26; Cohort 2: Cognitively unimpaired, a positive family history of MCI or AD, and MMSE ≥ 26; Cohort 3: An MMSE score > 22 and ≤ 25 and either; Clinically diagnosed MCI due to AD; A participant in a Wisconsin ADRC research registry with either clinically diagnosed MCI or self-reported MCI
  • Cohorts 1 and 2: proficient in independent use of mobile smart devices

Ki nem vehet részt

  • A cataract extraction within 3 months prior to enrollment
  • Current use of medications that may interfere with olfactory functions
  • A history of significant ocular or nasal trauma that required medical/surgical intervention
  • A history of intraocular surgery except cataract extraction
  • A history of recurrent or chronic oto-pharyngeal-laryngeal (ORL) disease (such as chronic rhinitis, nasal polyposis, or sinus disease), head trauma, toxic exposures, upper respiratory infections at time of assessment
  • A family history or diagnosis of other neurodegenerative diseases (e.g., multiple sclerosis, Parkinson's disease, Huntington's disease) or conditions that, in the opinion of the Investigators, may affect cognitive or olfactory functions
  • Olfactory loss due to COVID (current olfactory loss and/or temporary loss that has been regained)
  • Diagnosis of visually significant intraocular disease (such as late-stage age-related macular degeneration, glaucoma, or other optic nerve conditions related to brain tumor or multiple sclerosis), drug related vision loss or retinal damage
  • Optic neuritis on both eyes
  • Current use of hydroxychloroquine and tamoxifen, which are known to cause retinal toxicity that may confound OCT interpretation

Helyszínek itt: Egyesült Államok

  • University of WisconsinMadison, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to learn whether a new smell test works as well as the standard clinical smell test, if there is a link between sense of smell and variations in the retina, and if these results could be used as a way to identify early stages of Alzheimer's disease. The main questions it aims to answer are:

A teljes eredeti leírásKevesebb

* Whether the test is as effective and reliable as the standard test * Whether there is a link between the results of the smell test and the structure of the back of the eye

Participants will:

* complete a short questionnaire * have pictures of the inside of their eyes taken * perform two smell tests

A vizsgálat 3 csoportja

  • Cohort 1

    No cognitive impairment, and no family history of Alzheimer's disease

    Kezelés: ScentAware és UPSIT

  • Cohort 2

    No cognitive impairment, with a family history of Alzheimer's disease

    Kezelés: ScentAware és UPSIT

  • Cohort 3

    Mild cognitive impairment due to Alzheimer's disease

    Kezelés: ScentAware és UPSIT

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Proof-of-concept Pilot Study to Determine the Efficacy of SensifyAware and Retinal Imaging in Differentiating Mild Cognitive Impairment (MCI) From Cognitively Unimpaired Controls (HC)
A regiszteradat frissítve
2025. április 23.